elamipretide effects in adults with primary …...elamipretide effects in adults with primary...
TRANSCRIPT
Elamipretide Effects in Adults with Primary Mitochondrial Myopathy: Phase 2 Double-Blind, Randomized, Placebo-Controlled Crossover Trial (MMPOWER-2)
Authors: Karaa A1, Haas R2, Goldstein A3, Vockley G3, Cohen BH4
1Massachusetts General Hospital, Boston, MA., 2UC San Diego School of Medicine, San Diego, CA, 3Children’s Hospital of Pittsburgh, Pittsburgh, PA, 4Akron Children’s Hospital, Akron, OH
CONCLUSIONS
• ELAM-treated patients showed a 19.8-meter improvement in the 6MWT vs. placebo at the end of a 4-week treatment period
• ELAM participants had improved
– PMMSA Total Fatigue
– PMMSA Total Fatigue During Activities
– PMMSA “most bothersome” symptom score
– Neuro-QoL Fatigue-Short Form, and
• ELAM participants who walked <450 meters at baseline experienced a greater improvement in 6MWT (vs placebo) than participants who walked ≥450 meters at baseline
• There were no serious AEs
– The most frequently reported AE was local injection site reactions
– ELAM treatment was well tolerated by most participants
• Results of this trial are encouraging and support the initiation of a phase 3 trial
Procedures and Outcomes• Primary objective: To evaluate the effect of 4 weeks of a once daily dose of SC ELAM on
the distance walked during the 6MWT7
– Baseline and end of each treatment period values recorded (in meters)• Additional efficacy endpoints:
– Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) subscale scores7 (completed daily; assessed the severity of 10 most common PMM symptoms
Q Tiredness and muscle weakness at rest and during activities – PMMSA Total Fatigue During Activities score
Q Tiredness and muscle weakness during activities – Neuro-QoL Fatigue Item Bank8
• Secondary objectives – Evaluate the safety and tolerability of ELAM
Efficacy FindingsFunctional Assessments
• ELAM resulted in an improvement of 19.8 meters (6MWT - end of treatment period) compared with placebo (95% confidence interval [CI], -2.8, 42.5; p = 0.0833) Figure 5.
• ELAM patients reported less fatigue during activities as assessed by the PMMSA Total Fatigue During Activities score throughout the treatment period (Figure 7)
– ELAM treatment culminated in a 0.8-point reduction in symptom severity at the end of treatment vs. placebo (95% CI, -1.2, -0.3; p = 0.0018)
• Both scores, trended to return to baseline upon discontinuation of ELAM
– For individual items relating to myopathic symptoms of the individual PMMSA symptoms assessment, ELAM patients (vs placebo) had improvements in:
Q Tiredness at rest (p = 0.0008)
Q Tiredness during activities (p = 0.0046)
Q Muscle weakness at rest (p = 0.0007)
Q Muscle weakness during activities (p = 0.0019)
Q Muscle pain (p = 0.0079)
Q Severity of “most bothersome symptoms” (p = 0.0111)
Neuro-QoL Fatigue-Short Form
• ELAM therapy resulted in improved Neuro-QoL Fatigue-Short Form scores
– ELAM treatment yielded a 4-point reduction in the T-score vs. placebo (95% CI, -7.0, -1.0; p = 0.0115)
Safety Evaluation• Injection site reactions were the most commonly reported AEs with ELAM (80%) (Table 2)
• Most commonly characterized by erythema (57%), pruritus (47%), pain (20%), urticaria (20%), and irritation (10%)
• Seventy percent of patients reported mild injection site reactions such as moderate bruising, discomfort, erythema, induration, irritation, and/or pain
• During the trial, there were no serious AEs or deaths reported
INTRODUCTION
Trial Design and Participants
METHODS
RESULTS
REFERENCES
1. Mancuso M, Hirano M. NORD Physician Guide to Mitochondrial Myopathies (MM). Nat Org Rare Disord. 2016:1-8.
2. Mancuso M, McFarland R, Klopstock T, Hirano M. International workshop: outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Neuromuscul Disord. 2017:1-12. doi:10.1016/j.nmd.2017.08.006.
3. Pfeffer G, Horvath R, Klopstock T, et al. New treatments for mitochondrial disease—no time to drop our standards. Nat Rev Neurol. 2013;9(8):474-481. doi:10.1038/nrneurol.2013.129.New.
4. Tarnopolsky M. Exercise testing as a diagnostic entity in mitochondrial myopathies. Mitochondrion. 2004;4:529-542. doi:10.1016/j.mito.2004.07.011.
5. DiMauro S, Mancuso M, Naini A. Mitochondrial encephalomyopathies: Therapeutic approach. Ann N Y Acad Sci. 2004;1011:232-245. doi:10.1196/annals.1293.023.
6. Karaa A, Haas R, Goldstein A, Vockley J, Cohen B. Randomized dose-escalationtrialofelamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;0:1-10. Published Ahead of Print on March 2, 2018 as doi: 10.1212/WNL.0000000000005255
7. Crapo RO, Casaburi R, Coates AL, et al. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117. doi:10.1164/rccm.166/1/111.
8. Cella D, Lai JS, Nowinski CJ, et al. Neuro-QOL-Brief measures of health-related quality of life for clinical research in neurology. Neurology. 2012;78:1860-1867.
Acknowledgements:Patients and families for their participation. MitoAction and the United Mitochondrial Disease Foundation for helping with recruitment. We also thank Harvard Catalyst (http://catalyst.harvard.edu/about/citingsupport.html). Medical writing assistance was provided by Cathy R. Winter, PhD, and James A. Shiffer, RPh, Write On Time Medical Communications, LLC. Anthony Aiudi, PharmD (Stealth BT) edited the manuscript and tables for non-intellectual content. Jeffrey S. Finman, PhD Jupiter Point Pharma Consulting, LLC for statistical consultation. Study funding: Trial funded by Stealth BioTherapeutics, Newton, MA
Figure 2. MMPOWER Primary Endpoint: Change in Distance Walked at Day 5
20.4 13.5
36.5
64.5
(P=0.053)
0
10
20
30
40
50
60
70
80
90
Placebo Low Mid High
Mean Change Baseline to Day 5 (meters)
(0.01 mg/kg/hour) (0.1 mg/kg/hour) (0.25 mg/kg/hour)
Met
ers Dose Response
Assessed for eligibility (n=36)
Excluded (n=6)♦ Not meeting trial criteria (n=3) ♦ Declined to participate (n=2)♦ Other reasons (n=1)
When receiving ELAM: Analysed (n=30)♦ Excluded from analysis (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocated to ELAM (TP1), then to PBO (TP2) (n=14)♦ Received ELAM (n=14) ♦ Received PBO (n=14)
Lost to follow-up (n=0)
Discontinued intervention (n=1)♦
(n=♦♦
Allocated to PBO (TP1), then to ELAM (TP2) 16)
Received PBO (n=16) Received ELAM (n=16)
When receiving PBO: Analysed (n=30) ♦ Excluded from analysis (n=0)
Randomized (n=30)
eventDiscontinued ELAM (TP2) due to adverse
Allocation
Follow-Up
Enrollment*
ITT Analysis
Abbreviations: ELAM: elamipretide; PBO: placebo; TP1: Treatment Period 1; TP2: Treatment Period 2; ITT: Intent-to-Treat population* MMPOWER-2 was a multicenter, randomized, double-blind, placebo-controlled, crossover trial conducted in 4 US sites
Figure 4. MMPOWER-2 Consort Flow Diagram
Event, n (%)Elamipretide
N = 30Placebo
N=30
Injection site reactions
Erythema 17 (56.7) 1 (3.3)
Pruritus 14 (46.7) 0 (0)
Pain 6 (20.0) 1 (3.3)
Urticaria 6 (20.0) 0 (0)
Irritation 3 (10.0) 1 (3.3)
Bruising 2 (6.7) 2 (6.7)
Dizziness 3 (10.0) 1 (3.3)
Abdominal pain 2 (6.7) 1 (3.3)
Dysarthria 2 (6.7) 0 (0)
Urinary tract infection 2 (6.7) 0 (0)
Viral upper respiratory tract infection 2 (6.7) 0 (0)
Diarrhea 1 (3.3) 2 (6.7)
Fall 1 (3.3) 3 (10.0)
Muscle spasms 1 (3.3) 2 (6.7)
Back pain 0 (0) 2 (6.7)
Headache 0 (0) 2 (6.7)
Table 2. Treatment-emergent Adverse Events (AEs) (≥2 Participants)
Figure 3. MMPOWER-2 Study Design
Treatment period 1 Treatment period 2 Follow-upWashout
Crossover
Week 4
n=14 Elamipretide40 mg SC QD
Ran
dom
izat
ion
(1:1
)
Enr
ollm
ent
N =
30
Elamipretide40 mg SC QD
PlaceboSC QD
PlaceboSC QD
n=16
Week 8 Week 14Week 12
FIGURE 6. PMMSA Total Fatigue*
4
6
8
10
12
Pre-dose Week 1
*Total of 4 questions, each scored 1 = not at all, to 4 = severe (score range 4-16)
Week 2 Week 3 End of treatment period
Two weekspost-treatment
P = 0.0023
P = 0.0062P = 0.0283
P = 0.0006
P = 0.2247
Elamipretide Placebo
FIGURE 7. PMMSA Fatigue During Activities*
Pre-dose Week 1 Week 2 Week 3 End of treatment period
Two weekspost-treatment
Elamipretide Placebo
*Total of 2 questions, each scored 1 = not at all, to 4 = severe (score range 2-8)
3
4
5
7
P = 0.0085 P = 0.0557P = 0.0028 P = 0.0018
P = 0.1013
2
6
Elamipretide Placebo
Pre-dose Week 1 Week 2 Week 3 End of treatment period
Two weekspost-treatment
• Primary mitochondrial myopathies (PMMs) are genetic disorders that impair normal mitochondrial function, primarily affecting skeletal muscle,1,2 resulting in:
– decreased tolerance to physical exercise because of skeletal muscle respiratory chain dysfunction
– debilitating muscle weakness, muscle atrophy, limited exercise capacity, and symptoms of fatigue.
• The progression of PMM disease significantly compromises daily activity performance in the majority of cases3–5
• Currently, there are no US FDA–approved therapies for PMM
• An initial trial (MMPOWER) in genetically confirmed PMM patients evaluated 3 different daily IV doses of ELAM (0.01, 0.1, and 0.25 mg/kg/hour, for 2 hours) for 5 days. High dose ELAM treatment produced improvements in 6MWT6
• MMPOWER-2 evaluated chronic daily dosing of subcutaneous (SC) ELAM
Patient-Reported Outcomes
• ELAM participants reported less total fatigue as assessed by PMMSA Total Fatigue score throughout the treatment period (Figure 6)
– At the end of the treatment period, there was a 1.7-point reduction in symptom severity in ELAM participants compared with placebo (95% CI, -2.6, -0.8; p = 0.0006)
Figure 5. MMPOWER-2 Primary Endpoint: Change in Distance Walked Based on Measures of 6MWT
0
385
380
375
370
390
395
Ave
rage
Dis
tanc
e W
alke
din
6 M
WT
(met
ers)
400
End of Treatment Period
19.8 M (95% Cl, -2.8, 42.5; P = 0.08) Baseline
DistanceWalked
DifferenceElamipredtidevs Placebo (M)
<450 M
≥450 M
24.3*
8.6†
Subgroup Analysis Based onBaseline Distance Walked
6 Minute Walk Test
ElamipretidePlacebo
Pre-specified subgroup analysis:
*: n=22 (95% CI, -6.2, 54.7; p = 0.11)
†: n=8 (95% CI, -28.0, 45.2; p = 0.57)
Treatment sequence A:B
(ELAM:PBO)
n = 14
Treatment sequence B:A
(PBO:ELAM)
n = 16
All
Participants
N = 30
Age, mean (range), years 41.5 (17-63) 48.6 (25-65) 45.3 (17-65)
Gender, n (%) Female Male
10 (71)4 (29)
15 (94)1 (6)
25 (83)5 (17)
Race/ethnicity n (%)WhiteMultiple (white/Asian/other)Non-Hispanic or LatinoHispanic or Latino
13 (93)1 (7)14 (100)0
16 (100)015 (94)1 (6)
29 (97)1 (3)29 (97)1 (3)
Weight, mean (SD), kg 60.5 (±10.0) 69.2 (±16.3) 65.1 (±14.2)
BMI, mean (range), kg/m2 22.8 (15.8-33.2) 25.3 (19.0-36.0) 24.1 (15.8-36.0)
Baseline 6MWT, mean (SD), meters
381.2 (±30.4) 396.5 (±36.3) 389.4 (±23.6)
Baseline 6MWT, n (%),meters <450 ≥450
13 (93)1 (7)
9 (56)7 (44)
22 (73)8 (27)
Table 1. MMPOWER-2 Patient Baseline Characteristicss
Abbreviations: 6MWT = 6-minute walk test; BMI = body mass index; SD = standard deviation.
Demographic and Other Baseline Characteristics• Of the 36 eligible, genetically-confirmed participants from MMPOWER, 30 were
randomized in MMPOWER-2 (Table 1)Intermembrane space
Cardiolipin
Protonsaccumulate,
gradientdrives ATPproduction
Oxygen inintermembrane
space formsreactive oxygen
species
ELAM
ELAM
ELAM
ELAM
ELAM
ELAM
Lack of protons,reduced gradient,
reduced ATP
Electrons
Electronssupply energy
to pumpprotons
WaterATP
O2
O2
O2
ATP
ATP
ATP
ATP
O2
eO2
InnerMembrane
Healthy
• Adequate ATP Production
• Low ROS emission
• Electron carriers close to each other
• High membrane curvature
• Physiological cardiolipin content
• Diminished ATP Production
• High ROS emission
• Electron carriers spread apart
• Low membrane curvature
• Pathophysiological cardiolipin content
• Restoration of ATP Production
• Decreased ROS emission
• Electron carriers back together
• Higher membrane curvature
• Normalized cardiolipin content
Disease Elamipretide
Figure 1. Restoration of Mitochondrial Bioenergetics
SPIMM 202 MDA Poster_v4.indd 1 3/8/18 1:18 PM